Publications

  1. Early identification of weight loss trajectories in advanced cancer and associations with survival.

    Fuller S, Alexeeff S, Caan B, Dasilva Goncalves M, Dunne RF, Janowitz T, Jamal-Hanjani M, Sundaresan TK, Cespedes Feliciano EM.J Natl Cancer Inst. 2025 Feb 18:djaf030. doi: 10.1093/jnci/djaf030. Online ahead of print.PMID: 39961338

  2. Metabolic interplays between the tumour and the host shape the tumour macroenvironment.

    Altea-Manzano P, Decker-Farrell A, Janowitz T, Erez A.Nat Rev Cancer. 2025 Jan 20. doi: 10.1038/s41568-024-00786-4. Online ahead of print.PMID: 39833533 Review.

  3. Call to Improve Coding of Cancer-Associated Cachexia.

    Goncalves MD, Dunne RF, Moore AC, Phillips W, Heymsfield SB, Brown JC, Talbert EE, Janowitz T.JCO Oncol Pract. 2025 Jan 13:OP2400781. doi: 10.1200/OP-24-00781. Online ahead of print.PMID: 39805066

  4. Dietary pro-oxidant therapy by a vitamin K precursor targets PI 3-kinase VPS34 function.

    Swamynathan MM, Kuang S, Watrud KE, Doherty MR, Gineste C, Mathew G, Gong GQ, Cox H, Cheng E, Reiss D, Kendall J, Ghosh D, Reczek CR, Zhao X, Herzka T, Špokaitė S, Dessus AN, Kim ST, Klingbeil O, Liu J, Nowak DG, Alsudani H, Wee TL, Park Y, Minicozzi F, Rivera K, Almeida AS, Chang K, Chakrabarty RP, Wilkinson JE, Gimotty PA, Diermeier SD, Egeblad M, Vakoc CR, Locasale JW, Chandel NS, Janowitz T, Hicks JB, Wigler M, Pappin DJ, Williams RL, Cifani P, Tuveson DA, Laporte J, Trotman LC.Science. 2024 Oct 25;386(6720):eadk9167. doi: 10.1126/science.adk9167. Epub 2024 Oct 25.PMID: 39446948

  5. Inclusion of American Indian, Alaska Native, Native Hawaiian, and Pacific Islander Patients in Clinical Trial Travel Time-Reply.

    Lee H, Palafox NA, Janowitz T.JAMA Oncol. 2024 Oct 1;10(10):1441-1442. doi: 10.1001/jamaoncol.2024.3408.PMID: 39172490

  6. A guideline on the molecular ecosystem regulating ferroptosis.

    Dai E, Chen X, Linkermann A, Jiang X, Kang R, Kagan VE, Bayir H, Yang WS, Garcia-Saez AJ, Ioannou MS, Janowitz T, Ran Q, Gu W, Gan B, Krysko DV, Zhu X, Wang J, Krautwald S, Toyokuni S, Xie Y, Greten FR, Yi Q, Schick J, Liu J, Gabrilovich DI, Liu J, Zeh HJ, Zhang DD, Yang M, Iovanna J, Kopf M, Adolph TE, Chi JT, Li C, Ichijo H, Karin M, Sankaran VG, Zou W, Galluzzi L, Bush AI, Li B, Melino G, Baehrecke EH, Lotze MT, Klionsky DJ, Stockwell BR, Kroemer G, Tang D.Nat Cell Biol. 2024 Sep;26(9):1447-1457. doi: 10.1038/s41556-024-01360-8. Epub 2024 Feb 29.PMID: 38424270

  7. Why do patients with cancer die?

    Boire A, Burke K, Cox TR, Guise T, Jamal-Hanjani M, Janowitz T, Kaplan R, Lee R, Swanton C, Vander Heiden MG, Sahai E.Nat Rev Cancer. 2024 Aug;24(8):578-589. doi: 10.1038/s41568-024-00708-4. Epub 2024 Jun 19.PMID: 38898221

  8. Restoring adiponectin via rosiglitazone ameliorates tissue wasting in mice with lung cancer.

    Langer HT, Ramsamooj S, Dantas E, Murthy A, Ahmed M, Ahmed T, Hwang SK, Grover R, Pozovskiy R, Liang RJ, Queiroz AL, Brown JC, White EP, Janowitz T, Goncalves MD. Acta Physiol (Oxf). 2024 Aug;240(8):e14167. doi: 10.1111/apha.14167. Epub 2024 May 23.PMID: 38779820

  9. Area postrema neurons mediate interleukin-6 function in cancer cachexia.

    Sun Q, van de Lisdonk D, Ferrer M, Gegenhuber B, Wu M, Park Y, Tuveson DA, Tollkuhn J, Janowitz T, Li B. Nat Commun. 2024 Jun 1;15(1):4682. doi: 10.1038/s41467-024-48971-1.PMID: 38824130

  10. Analysis and Optimization of Equitable US Cancer Clinical Trial Center Access by Travel Time.

    Lee H, Bates AS, Callier S, Chan M, Chambwe N, Marshall A, Terry MB, Winkfield K, Janowitz T. JAMA Oncol. 2024 May 1;10(5):652-657. doi: 10.1001/jamaoncol.2023.7314.PMID: 38512297

  11. Opportunities and challenges for innovative and equitable healthcare.

    Ecker DJ, Aiello CD, Arron JR, Bennett CF, Bernard A, Breakefield XO, Broderick TJ, Callier SL, Canton B, Chen JS, Fishburn CS, Garrett B, Hecht SM, Janowitz T, Kliegman M, Krainer A, Louis CU, Lowe C, Sehgal A, Tozan Y, Tracey KJ, Urnov F, Wattendorf D, Williams TW, Zhao X, Hayden MR.Nat Rev Drug Discov. 2024 May;23(5):321-322. doi: 10.1038/d41573-024-00032-4.PMID: 38409339

  12. Sensitive, non-immunogenic in vivo imaging of cancer metastases and immunotherapy response.

    Merrill JR, Inguscio A, Chung T, Demestichas B, Garcia LA, Habel J, Lewis DY, Janowitz T, Lyons SK. Cell Stress. 2023 Aug 14;7(8):59-68. doi: 10.15698/cst2023.08.288. eCollection 2023 Aug 14.PMID: 37664695

  13. Cystatin C is glucocorticoid responsive, directs recruitment of Trem2+ macrophages, and predicts failure of cancer immunotherapy.

    Kleeman SO, Thakir TM, Demestichas B, Mourikis N, Loiero D, Ferrer M, Bankier S, Riazat-Kesh YJRA, Lee H, Chantzichristos D, Regan C, Preall J, Sinha S, Rosin N, Yipp B, de Almeida LGN, Biernaskie J, Dufour A, Tober-Lau P, Ruusalepp A, Bjorkegren JLM, Ralser M, Kurth F, Demichev V, Heywood T, Gao Q, Johannsson G, Koelzer VH, Walker BR, Meyer HV, Janowitz T.Cell Genom. 2023 Jun 23;3(8):100347. doi: 10.1016/j.xgen.2023.100347. eCollection 2023 Aug 9.PMID: 37601967

  14. Restoring adiponectin via rosiglitazone ameliorates tissue wasting in mice with lung cancer.

    Langer HT, Ramsamooj S, Dantas E, Murthy A, Ahmed M, Hwang SK, Grover R, Pozovskiy R, Liang RJ, Queiroz AL, Brown JC, White EP, Janowitz T, Goncalves AMD.bioRxiv [Preprint]. 2023 Aug 2:2023.07.31.551241. doi: 10.1101/2023.07.31.551241.Update in: Acta Physiol (Oxf). 2024 Aug;240(8):e14167. doi: 10.1111/apha.14167.PMID: 37577571

  15. Ketogenic diet promotes tumor ferroptosis but induces relative corticosterone deficiency that accelerates cachexia.

    Ferrer M, Mourikis N, Davidson EE, Kleeman SO, Zaccaria M, Habel J, Rubino R, Gao Q, Flint TR, Young L, Connell CM, Lukey MJ, Goncalves MD, White EP, Venkitaraman AR, Janowitz T.Cell Metab. 2023 Jul 11;35(7):1147-1162.e7. doi: 10.1016/j.cmet.2023.05.008. Epub 2023 Jun 12.PMID: 37311455

  16. Tumor Cytokine-Induced Hepatic Gluconeogenesis Contributes to Cancer Cachexia: Insights from Full Body Single Nuclei Sequencing.

    Liu Y, Dantas E, Ferrer M, Liu Y, Comjean A, Davidson EE, Hu Y, Goncalves MD, Janowitz T, Perrimon N.bioRxiv [Preprint]. 2023 May 18:2023.05.15.540823. doi: 10.1101/2023.05.15.540823.PMID: 37292804

  17. Cachexia: A systemic consequence of progressive, unresolved disease.

    Ferrer M, Anthony TG, Ayres JS, Biffi G, Brown JC, Caan BJ, Cespedes Feliciano EM, Coll AP, Dunne RF, Goncalves MD, Grethlein J, Heymsfield SB, Hui S, Jamal-Hanjani M, Lam JM, Lewis DY, McCandlish D, Mustian KM, O'Rahilly S, Perrimon N, White EP, Janowitz T.Cell. 2023 Apr 27;186(9):1824-1845. doi: 10.1016/j.cell.2023.03.028.PMID: 37116469

  18. CRISPR-induced exon skipping of β-catenin reveals tumorigenic mutants driving distinct subtypes of liver cancer.

    Mou H, Eskiocak O, Özler KA, Gorman M, Yue J, Jin Y, Wang Z, Gao Y, Janowitz T, Meyer HV, Yu T, Wilkinson JE, Kucukural A, Ozata DM, Beyaz S.J Pathol. 2023 Apr;259(4):415-427. doi: 10.1002/path.6054. Epub 2023 Feb 8.PMID: 36641763

  19. Ketogenic diet promotes tumor ferroptosis but induces relative corticosterone deficiency that accelerates cachexia.

    Ferrer M, Mourikis N, Davidson EE, Kleeman SO, Zaccaria M, Habel J, Rubino R, Flint TR, Connell CM, Lukey MJ, White EP, Coll AP, Venkitaraman AR, Janowitz T.bioRxiv [Preprint]. 2023 Feb 18:2023.02.17.528937. doi: 10.1101/2023.02.17.528937.Update in: Cell Metab. 2023 Jul 11;35(7):1147-1162.e7. doi: 10.1016/j.cmet.2023.05.008.PMID: 36824830

  20. Area postrema neurons mediate interleukin-6 function in cancer-associated cachexia.

    Sun Q, van de Lisdonk D, Ferrer M, Gegenhuber B, Wu M, Tollkuhn J, Janowitz T, Li B.bioRxiv [Preprint]. 2023 Jan 14:2023.01.12.523716. doi: 10.1101/2023.01.12.523716.Update in: Nat Commun. 2024 Jun 1;15(1):4682. doi: 10.1038/s41467-024-48971-1.PMID: 36711916

  21. Neurotensin neurons in the extended amygdala control dietary choice and energy homeostasis.

    Furlan A, Corona A, Boyle S, Sharma R, Rubino R, Habel J, Gablenz EC, Giovanniello J, Beyaz S, Janowitz T, Shea SD, Li B.Nat Neurosci. 2022 Nov;25(11):1470-1480. doi: 10.1038/s41593-022-01178-3. Epub 2022 Oct 20.PMID: 36266470

  22. Cystatin C is associated with adverse COVID-19 outcomes in diverse populations.

    Kleeman SO, Cordioli M, Timmers PRHJ, Khan A, Tober-Lau P, Kurth F, Demichev V, Meyer HV, Wilson JF, Ralser M, Kiryluk K, Ganna A, Baillie K, Janowitz T.iScience. 2022 Oct 21;25(10):105040. doi: 10.1016/j.isci.2022.105040. Epub 2022 Aug 31.PMID: 36062073

  23. PTP1B inhibitors protect against acute lung injury and regulate CXCR4 signaling in neutrophils.

    Song D, Adrover JM, Felice C, Christensen LN, He XY, Merrill JR, Wilkinson JE, Janowitz T, Lyons SK, Egeblad M, Tonks NK.JCI Insight. 2022 Jul 22;7(14):e158199. doi: 10.1172/jci.insight.158199.PMID: 35866483

  24. Training the host organism to enhance anti-cancer immunity.

    Ferrer M, Janowitz T.Cancer Cell. 2022 Jul 11;40(7):703-705. doi: 10.1016/j.ccell.2022.06.003. Epub 2022 Jun 23.PMID: 35750051

  25. Oral famotidine versus placebo in non-hospitalised patients with COVID-19: a randomised, double-blind, data-intense, phase 2 clinical trial.

    Brennan CM, Nadella S, Zhao X, Dima RJ, Jordan-Martin N, Demestichas BR, Kleeman SO, Ferrer M, von Gablenz EC, Mourikis N, Rubin ME, Adnani H, Lee H, Ha T, Prum S, Schleicher CB, Fox SS, Ryan MG, Pili C, Goldberg G, Crawford JM, Goodwin S, Zhang X, Preall JB, Costa ASH, Conigliaro J, Masci JR, Yang J, Tuveson DA, Tracey KJ, Janowitz T.Gut. 2022 May;71(5):879-888. doi: 10.1136/gutjnl-2022-326952. Epub 2022 Feb 10.PMID: 35144974

  26. Early Neutrophilia Marked by Aerobic Glycolysis Sustains Host Metabolism and Delays Cancer Cachexia.

    Petruzzelli M, Ferrer M, Schuijs MJ, Kleeman SO, Mourikis N, Hall Z, Perera D, Raghunathan S, Vacca M, Gaude E, Lukey MJ, Jodrell DI, Frezza C, Wagner EF, Venkitaraman AR, Halim TYF, Janowitz T.Cancers (Basel). 2022 Feb 15;14(4):963. doi: 10.3390/cancers14040963.PMID: 35205709

  27. Carcinomas assemble a filamentous CXCL12-keratin-19 coating that suppresses T cell-mediated immune attack.

    Wang Z, Moresco P, Yan R, Li J, Gao Y, Biasci D, Yao M, Pearson J, Hechtman JF, Janowitz T, Zaidi RM, Weiss MJ, Fearon DT.Proc Natl Acad Sci U S A. 2022 Jan 25;119(4):e2119463119. doi: 10.1073/pnas.2119463119.PMID: 35046049

  28. Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma.

    Kolamunnage-Dona R, Berhane S, Potts H, Williams EH, Tanner J, Janowitz T, Hoare M, Johnson P.J Hepatol. 2021 Oct;75(4):879-887. doi: 10.1016/j.jhep.2021.05.015. Epub 2021 May 27.PMID: 34052255

  29. Enhancing the Efficacy of Glutamine Metabolism Inhibitors in Cancer Therapy.

    Yang WH, Qiu Y, Stamatatos O, Janowitz T, Lukey MJ.Trends Cancer. 2021 Aug;7(8):790-804. doi: 10.1016/j.trecan.2021.04.003. Epub 2021 May 18.PMID: 34020912

  30. AMD3100/Plerixafor overcomes immune inhibition by the CXCL12-KRT19 coating on pancreatic and colorectal cancer cells.

    Fearon DT, Janowitz T.Br J Cancer. 2021 Jul;125(2):149-151. doi: 10.1038/s41416-021-01315-y. Epub 2021 Mar 26.PMID: 33772153

  31. Reconsidering Dexamethasone for Antiemesis when Combining Chemotherapy and Immunotherapy.

    Janowitz T, Kleeman S, Vonderheide RH.Oncologist. 2021 Apr;26(4):269-273. doi: 10.1002/onco.13680. Epub 2021 Feb 26.PMID: 33465258

  32. CamGFR v2: A New Model for Estimating the Glomerular Filtration Rate from Standardized or Non-standardized Creatinine in Patients with Cancer.

    Williams EH, Flint TR, Connell CM, Giglio D, Lee H, Ha T, Gablenz E, Bird NJ, Weaver JMJ, Potts H, Whitley CT, Bookman MA, Lynch AG, Meyer HV, Tavaré S, Janowitz T.Clin Cancer Res. 2021 Mar 1;27(5):1381-1390. doi: 10.1158/1078-0432.CCR-20-3201. Epub 2020 Dec 10.PMID: 33303580

  33. Stromal-driven and Amyloid β-dependent induction of neutrophil extracellular traps modulates tumor growth.

    Munir H, Jones JO, Janowitz T, Hoffmann M, Euler M, Martins CP, Welsh SJ, Shields JD.Nat Commun. 2021 Jan 29;12(1):683. doi: 10.1038/s41467-021-20982-2.PMID: 33514748

  34. CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response.

    Biasci D, Smoragiewicz M, Connell CM, Wang Z, Gao Y, Thaventhiran JED, Basu B, Magiera L, Johnson TI, Bax L, Gopinathan A, Isherwood C, Gallagher FA, Pawula M, Hudecova I, Gale D, Rosenfeld N, Barmpounakis P, Popa EC, Brais R, Godfrey E, Mir F, Richards FM, Fearon DT, Janowitz T, Jodrell DI.Proc Natl Acad Sci U S A. 2020 Nov 17;117(46):28960-28970. doi: 10.1073/pnas.2013644117. Epub 2020 Oct 30.PMID: 33127761

  35. Nebulized in-line endotracheal dornase alfa and albuterol administered to mechanically ventilated COVID-19 patients: a case series.

    Weber AG, Chau AS, Egeblad M, Barnes BJ, Janowitz T.Mol Med. 2020 Sep 29;26(1):91. doi: 10.1186/s10020-020-00215-w.PMID: 32993479

  36. Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series.

    Janowitz T, Gablenz E, Pattinson D, Wang TC, Conigliaro J, Tracey K, Tuveson D.Gut. 2020 Sep;69(9):1592-1597. doi: 10.1136/gutjnl-2020-321852. Epub 2020 Jun 4.PMID: 32499303

  37. The Era of COVID-19 and the Rise of Science Collectivism in Cancer Research.

    Janowitz T, Tuveson DA.Cancer Discov. 2020 Jul;10(7):913-915. doi: 10.1158/2159-8290.CD-20-0657. Epub 2020 May 13.PMID: 32404307

  38. Nebulized in-line endotracheal dornase alfa and albuterol administered to mechanically ventilated COVID-19 patients: A case series.

    Weber AG, Chau AS, Egeblad M, Barnes BJ, Janowitz T.medRxiv [Preprint]. 2020 May 15:2020.05.13.20087734. doi: 10.1101/2020.05.13.20087734.Update in: Mol Med. 2020 Sep 29;26(1):91. doi: 10.1186/s10020-020-00215-w.PMID: 32511514

  39. A framework for advancing our understanding of cancer-associated fibroblasts.

    Sahai E, Astsaturov I, Cukierman E, DeNardo DG, Egeblad M, Evans RM, Fearon D, Greten FR, Hingorani SR, Hunter T, Hynes RO, Jain RK, Janowitz T, Jorgensen C, Kimmelman AC, Kolonin MG, Maki RG, Powers RS, Puré E, Ramirez DC, Scherz-Shouval R, Sherman MH, Stewart S, Tlsty TD, Tuveson DA, Watt FM, Weaver V, Weeraratna AT, Werb Z.Nat Rev Cancer. 2020 Mar;20(3):174-186. doi: 10.1038/s41568-019-0238-1. Epub 2020 Jan 24.PMID: 31980749

  40. Early relapse on adjuvant gemcitabine associated with an exceptional response to 2nd line capecitabine chemotherapy in a patient with pancreatic adenosquamous carcinoma with strong intra-tumoural expression of cytidine deaminase: a case report.

    Connell CM, Brais R, Whitaker H, Upponi S, Beh I, Risdall J, Corrie P, Janowitz T, Jodrell DI.BMC Cancer. 2020 Jan 15;20(1):38. doi: 10.1186/s12885-020-6516-1.PMID: 31941506

  41. Multicenter Validation of the CamGFR Model for Estimated Glomerular Filtration Rate.

    Williams EH, Connell CM, Weaver JMJ, Beh I, Potts H, Whitley CT, Bird N, Al-Sayed T, Monaghan PJ, Fehr M, Cathomas R, Bertelli G, Quinton A, Lewis P, Shamash J, Wilson P, Dooley M, Poole S, Mark PB, Bookman MA, Earl H, Jodrell D, Tavaré S, Lynch AG, Janowitz T.JNCI Cancer Spectr. 2019 Sep 19;3(4):pkz068. doi: 10.1093/jncics/pkz068. eCollection 2019 Dec.PMID: 31750418

  42. Oncogenic KRAS Reduces Expression of FGF21 in Acinar Cells to Promote Pancreatic Tumorigenesis in Mice on a High-Fat Diet.

    Luo Y, Yang Y, Liu M, Wang D, Wang F, Bi Y, Ji J, Li S, Liu Y, Chen R, Huang H, Wang X, Swidnicka-Siergiejko AK, Janowitz T, Beyaz S, Wang G, Xu S, Bialkowska AB, Luo CK, Pin CL, Liang G, Lu X, Wu M, Shroyer KR, Wolff RA, Plunkett W, Ji B, Li Z, Li E, Li X, Yang VW, Logsdon CD, Abbruzzese JL, Lu W.Gastroenterology. 2019 Nov;157(5):1413-1428.e11. doi: 10.1053/j.gastro.2019.07.030. Epub 2019 Jul 25.PMID: 31352001

  43. Cancer: The Tumor-Driven Disease of the Host.

    Janowitz T.Cell Metab. 2018 Jul 3;28(1):5-6. doi: 10.1016/j.cmet.2018.06.016.PMID: 29972797

  44. A type III complement factor D deficiency: Structural insights for inhibition of the alternative pathway.

    Sng CCT, O'Byrne S, Prigozhin DM, Bauer MR, Harvey JC, Ruhle M, Challis BG, Lear S, Roberts LD, Workman S, Janowitz T, Magiera L, Doffinger R, Buckland MS, Jodrell DJ, Semple RK, Wilson TJ, Modis Y, Thaventhiran JED.J Allergy Clin Immunol. 2018 Jul;142(1):311-314.e6. doi: 10.1016/j.jaci.2018.01.048. Epub 2018 Mar 6.PMID: 29522842

  45. A comparative analysis of immune privilege in pregnancy and cancer in the context of checkpoint blockade immunotherapy.

    Flint TR, Jones JO, Ferrer M, Colucci F, Janowitz T.Semin Oncol. 2018 Jun;45(3):170-175. doi: 10.1053/j.seminoncol.2018.03.005. Epub 2018 Mar 26.PMID: 30262396

  46. Cancer Immunotherapy Trials Underutilize Immune Response Monitoring.

    Connell CM, Raby SEM, Beh I, Flint TR, Williams EH, Fearon DT, Jodrell DI, Janowitz T.Oncologist. 2018 Jan;23(1):116-117. doi: 10.1634/theoncologist.2017-0226. Epub 2017 Oct 11.PMID: 29021379

  47. New Model for Estimating Glomerular Filtration Rate in Patients With Cancer.

    Janowitz T, Williams EH, Marshall A, Ainsworth N, Thomas PB, Sammut SJ, Shepherd S, White J, Mark PB, Lynch AG, Jodrell DI, Tavaré S, Earl H.J Clin Oncol. 2017 Aug 20;35(24):2798-2805. doi: 10.1200/JCO.2017.72.7578. Epub 2017 Jul 7.PMID: 28686534

  48. Connecting the Metabolic and Immune Responses to Cancer.

    Flint TR, Fearon DT, Janowitz T.Trends Mol Med. 2017 May;23(5):451-464. doi: 10.1016/j.molmed.2017.03.001. Epub 2017 Apr 7.PMID: 28396056

  49. A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab.

    Fessas P, Lee H, Ikemizu S, Janowitz T.Semin Oncol. 2017 Apr;44(2):136-140. doi: 10.1053/j.seminoncol.2017.06.002. Epub 2017 Jul 4.PMID: 28923212

  50. Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor Immunity.

    Flint TR, Janowitz T, Connell CM, Roberts EW, Denton AE, Coll AP, Jodrell DI, Fearon DT.Cell Metab. 2016 Nov 8;24(5):672-684. doi: 10.1016/j.cmet.2016.10.010.PMID: 27829137

  51. Chemotherapy vs supportive care alone for relapsed gastric, gastroesophageal junction, and oesophageal adenocarcinoma: a meta-analysis of patient-level data.

    Janowitz T, Thuss-Patience P, Marshall A, Kang JH, Connell C, Cook N, Dunn J, Park SH, Ford H.Br J Cancer. 2016 Feb 16;114(4):381-7. doi: 10.1038/bjc.2015.452.PMID: 26882063

  52. Prostatic relapse of an undifferentiated teratoma 24 years after orchidectomy.

    Janowitz T, Welsh S, Warren AY, Robson J, Thomas B, Shaw A, Ainsworth NL, Neal DE, Mazhar D.BMC Res Notes. 2015 Oct 1;8:524. doi: 10.1186/s13104-015-1445-9.PMID: 26428307

  53. The use of error-category mapping in pharmacokinetic model analysis of dynamic contrast-enhanced MRI data.

    Gill AB, Anandappa G, Patterson AJ, Priest AN, Graves MJ, Janowitz T, Jodrell DI, Eisen T, Lomas DJ.Magn Reson Imaging. 2015 Feb;33(2):246-51. doi: 10.1016/j.mri.2014.10.010. Epub 2014 Nov 7.PMID: 25460333

  54. Cross-sectional and longitudinal analysis of cancer vaccination trials registered on the US Clinical Trials Database demonstrates paucity of immunological trial endpoints and decline in registration since 2008.

    Lu L, Yan H, Shyam-Sundar V, Janowitz T.Drug Des Devel Ther. 2014 Sep 27;8:1539-53. doi: 10.2147/DDDT.S65963. eCollection 2014.PMID: 25302014

  55. Panhypopituitarism secondary to a solitary hypothalamic metastasis.

    Ellul M, Janowitz T, Burnet N.BMJ Case Rep. 2014 May 23;2014:bcr2014204283. doi: 10.1136/bcr-2014-204283.PMID: 24859558

  56. Cross-sectional analysis of data from the U.S. clinical trials database reveals poor translational clinical trial effort for traumatic brain injury, compared with stroke.

    Li LM, Menon DK, Janowitz T.PLoS One. 2014 Jan 8;9(1):e84336. doi: 10.1371/journal.pone.0084336. eCollection 2014.PMID: 24416218

  57. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial.

    Ford HE, Marshall A, Bridgewater JA, Janowitz T, Coxon FY, Wadsley J, Mansoor W, Fyfe D, Madhusudan S, Middleton GW, Swinson D, Falk S, Chau I, Cunningham D, Kareclas P, Cook N, Blazeby JM, Dunn JA; COUGAR-02 Investigators.Lancet Oncol. 2014 Jan;15(1):78-86. doi: 10.1016/S1470-2045(13)70549-7. Epub 2013 Dec 10.PMID: 24332238

  58. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer.

    Feig C, Jones JO, Kraman M, Wells RJ, Deonarine A, Chan DS, Connell CM, Roberts EW, Zhao Q, Caballero OL, Teichmann SA, Janowitz T, Jodrell DI, Tuveson DA, Fearon DT.Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20212-7. doi: 10.1073/pnas.1320318110. Epub 2013 Nov 25.PMID: 24277834

  59. Adjuvant therapy in renal cell carcinoma-past, present, and future.

    Janowitz T, Welsh SJ, Zaki K, Mulders P, Eisen T.Semin Oncol. 2013 Aug;40(4):482-91. doi: 10.1053/j.seminoncol.2013.05.004.PMID: 23972712

  60. Targeted metabolomics identifies perturbations in amino acid metabolism that sub-classify patients with COPD.

    Ubhi BK, Cheng KK, Dong J, Janowitz T, Jodrell D, Tal-Singer R, MacNee W, Lomas DA, Riley JH, Griffin JL, Connor SC.Mol Biosyst. 2012 Oct 30;8(12):3125-33. doi: 10.1039/c2mb25194a.PMID: 23051772 Clinical Trial.

  61. Janowitz, T. (January 2011) Biopharmaceuticals and monoclonal antibodies in oncology trials--a cross-sectional analysis. Protein Eng Des Sel, 24 (1-2). pp. 105-11. ISSN 1741-0126

  62. Janowitz, T., Menon, D. K. (April 2010) Exploring new routes for neuroprotective drug development in traumatic brain injury. Sci Transl Med, 2 (27). 27rv1. ISSN 1946-6234

  63. Oliynyk, Z., Briseno-Roa, L., Janowitz, T., Sondergeld, P., Fersht, A. R. (April 2004) Designing a metal-binding site in the scaffold of Escherichia coli KDO8PS. Protein Eng Des Sel, 17 (4). pp. 383-90. ISSN 1741-0126 (Print)1741-0126

  64. Koulen, P., Janowitz, T., Johenning, F. W., Ehrlich, B. E. (October 2001) Characterization of the calcium-release channel/ryanodine receptor from zebrafish skeletal muscle. J Membr Biol, 183 (3). pp. 155-63. ISSN 0022-2631 (Print)0022-2631

  65. Koulen, P., Janowitz, T., Johnston, L. D., Ehrlich, B. E. (September 2000) Conservation of localization patterns of IP(3) receptor type 1 in cerebellar Purkinje cells across vertebrate species. J Neurosci Res, 61 (5). pp. 493-9. ISSN 0360-4012 (Print)0360-4012